Annie Umbricht - Publications

Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine, Baltimore, MD, United States 

38 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Huhn AS, Hobelmann JG, Strickland JC, Oyler GA, Bergeria CL, Umbricht A, Dunn KE. Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States. Jama Network Open. 3: e1920843. PMID 32031650 DOI: 10.1001/jamanetworkopen.2019.20843  0.4
2016 Jarvis BP, Holtyn AF, DeFulio A, Dunn KE, Everly JJ, Leoutsakos JS, Umbricht A, Fingerhood M, Bigelow GE, Silverman K. Effects of incentives for naltrexone adherence on opiate abstinence in heroin-dependent adults. Addiction (Abingdon, England). PMID 27936293 DOI: 10.1111/add.13724  0.4
2015 Dunn K, Marcus T, Kim C, Schroeder JR, Vandrey R, Umbricht A. Zonisamide Reduces Withdrawal Symptoms But Does Not Enhance Varenicline-induced Smoking Cessation. Nicotine & Tobacco Research : Official Journal of the Society For Research On Nicotine and Tobacco. PMID 26476459 DOI: 10.1093/ntr/ntv236  0.4
2015 Rass O, Umbricht A, Bigelow GE, Strain EC, Johnson MW, Mintzer MZ. Topiramate impairs cognitive function in methadone-maintained individuals with concurrent cocaine dependence. Psychology of Addictive Behaviors : Journal of the Society of Psychologists in Addictive Behaviors. 29: 237-46. PMID 25365653 DOI: 10.1037/adb0000027  0.4
2015 Dunn K, DeFulio A, Everly JJ, Donlin WD, Aklin WM, Nuzzo PA, Leoutsakos JM, Umbricht A, Fingerhood M, Bigelow GE, Silverman K. Employment-based reinforcement of adherence to oral naltrexone in unemployed injection drug users: 12-month outcomes. Psychology of Addictive Behaviors : Journal of the Society of Psychologists in Addictive Behaviors. 29: 270-6. PMID 25134047 DOI: 10.1037/adb0000010  0.4
2014 Hossain SM, Ali AA, Rahman M, Ertin E, Epstein D, Kennedy A, Preston K, Umbricht A, Chen Y, Kumar S. Identifying Drug (Cocaine) Intake Events from Acute Physiological Response in the Presence of Free-living Physical Activity. Ipsn : [Proceedings] / International Symposium On Information Processing in Sensor Networks. Ipsn (Conference). 2014: 71-82. PMID 25531010 DOI: 10.1109/IPSN.2014.6846742  0.4
2014 Umbricht A, DeFulio A, Winstanley EL, Tompkins DA, Peirce J, Mintzer MZ, Strain EC, Bigelow GE. Topiramate for cocaine dependence during methadone maintenance treatment: a randomized controlled trial. Drug and Alcohol Dependence. 140: 92-100. PMID 24814607 DOI: 10.1016/j.drugalcdep.2014.03.033  0.4
2013 Huestis MA, Cone EJ, Pirnay SO, Umbricht A, Preston KL. Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans Drug and Alcohol Dependence. 131: 258-262. PMID 23246635 DOI: 10.1016/j.drugalcdep.2012.11.014  0.4
2013 Dunn KE, Defulio A, Everly JJ, Donlin WD, Aklin WM, Nuzzo PA, Leoutsakos JM, Umbricht A, Fingerhood M, Bigelow GE, Silverman K. Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users. Experimental and Clinical Psychopharmacology. 21: 74-83. PMID 23205722 DOI: 10.1037/a0030743  0.4
2012 Aklin WM, Severtson SG, Umbricht A, Fingerhood M, Bigelow GE, Lejuez CW, Silverman K. Risk-taking propensity as a predictor of induction onto naltrexone treatment for opioid dependence. The Journal of Clinical Psychiatry. 73: e1056-61. PMID 22967782 DOI: 10.4088/JCP.09m05807  0.4
2012 Henry PK, Umbricht A, Kleykamp BA, Vandrey R, Strain EC, Bigelow GE, Mintzer MZ. Comparison of cognitive performance in methadone maintenance patients with and without current cocaine dependence. Drug and Alcohol Dependence. 124: 167-71. PMID 22266090 DOI: 10.1016/j.drugalcdep.2011.12.009  0.4
2012 DeFulio A, Everly JJ, Leoutsakos JM, Umbricht A, Fingerhood M, Bigelow GE, Silverman K. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial. Drug and Alcohol Dependence. 120: 48-54. PMID 21782353 DOI: 10.1016/j.drugalcdep.2011.06.023  0.4
2011 Vandrey R, Umbricht A, Strain EC. Increased blood pressure after abrupt cessation of daily cannabis use Journal of Addiction Medicine. 5: 16-20. PMID 21359104 DOI: 10.1097/ADM.0b013e3181d2b309  0.4
2011 Everly JJ, DeFulio A, Koffarnus MN, Leoutsakos JM, Donlin WD, Aklin WM, Umbricht A, Fingerhood M, Bigelow GE, Silverman K. Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial. Addiction (Abingdon, England). 106: 1309-18. PMID 21320227 DOI: 10.1111/j.1360-0443.2011.03400.x  0.4
2010 Walsh SL, Donny EC, Nuzzo PA, Umbricht A, Bigelow GE. Cocaine abuse versus cocaine dependence: Cocaine self-administration and pharmacodynamic response in the human laboratory Drug and Alcohol Dependence. 106: 28-37. PMID 19717246 DOI: 10.1016/j.drugalcdep.2009.07.011  0.4
2009 Epstein DH, Schmittner J, Umbricht A, Schroeder JR, Moolchan ET, Preston KL. Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency. Drug and Alcohol Dependence. 101: 92-100. PMID 19101098 DOI: 10.1016/j.drugalcdep.2008.11.006  0.4
2008 Lanier RK, Umbricht A, Harrison JA, Nuwayser ES, Bigelow GE. Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: an open-label evaluation. Psychopharmacology. 198: 149-58. PMID 18327673 DOI: 10.1007/s00213-008-1105-z  0.4
2007 Lanier RK, Umbricht A, Harrison JA, Nuwayser ES, Bigelow GE. Evaluation of a transdermal buprenorphine formulation in opioid detoxification. Addiction (Abingdon, England). 102: 1648-56. PMID 17854341 DOI: 10.1111/j.1360-0443.2007.01944.x  0.4
2006 Schroeder JR, Epstein DH, Umbricht A, Preston KL. Changes in HIV risk behaviors among patients receiving combined pharmacological and behavioral interventions for heroin and cocaine dependence. Addictive Behaviors. 31: 868-79. PMID 16085366 DOI: 10.1016/j.addbeh.2005.07.009  0.4
2005 Montoya ID, Schroeder JR, Preston KL, Covi L, Umbricht A, Contoreggi C, Fudala PJ, Johnson RE, Gorelick DA. Influence of psychotherapy attendance on buprenorphine treatment outcome. Journal of Substance Abuse Treatment. 28: 247-54. PMID 15857725 DOI: 10.1016/j.jsat.2005.01.004  0.4
2004 Boyd SJ, Thomas-Gosain NF, Umbricht A, Tucker MJ, Leslie JM, Chaisson RE, Preston KL. Gender differences in indices of opioid dependency and medical comorbidity in a population of hospitalized HIV-infected African-Americans. The American Journal On Addictions / American Academy of Psychiatrists in Alcoholism and Addictions. 13: 281-91. PMID 15370947 DOI: 10.1080/10550490490459960  0.4
2004 Umbricht A, Huestis MA, Cone EJ, Preston KL. Effects of high-dose intravenous buprenorphine in experienced opioid abusers Journal of Clinical Psychopharmacology. 24: 479-487. PMID 15349002 DOI: 10.1097/  0.4
2004 Pickworth WB, Lee EM, Abreu ME, Umbricht A, Preston KL. A laboratory study of hydromorphone and cyclazocine on smoking behavior in residential polydrug users Pharmacology Biochemistry and Behavior. 77: 711-715. PMID 15099916 DOI: 10.1016/j.pbb.2004.01.022  0.4
2004 Preston KL, Umbricht A, Schroeder JR, Abreu ME, Epstein DH, Pickworth WB. Cyclazocine: comparison to hydromorphone and interaction with cocaine. Behavioural Pharmacology. 15: 91-102. PMID 15096909 DOI: 10.1097/00008877-200403000-00001  0.4
2004 Montoya ID, Gorelick DA, Preston KL, Schroeder JR, Umbricht A, Cheskin LJ, Lange WR, Contoreggi C, Johnson RE, Fudala PJ. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clinical Pharmacology and Therapeutics. 75: 34-48. PMID 14749690 DOI: 10.1016/j.clpt.2003.09.004  0.4
2003 Schroeder JR, Gupman AE, Epstein DH, Umbricht A, Preston KL. Do noncontingent vouchers increase drug use? Experimental and Clinical Psychopharmacology. 11: 195-201. PMID 12940498 DOI: 10.1037/1064-1297.11.3.195  0.4
2003 Epstein DH, Hawkins WE, Covi L, Umbricht A, Preston KL. Cognitive-behavioral therapy plus contingency management for cocaine use: Findings during treatment and across 12-month follow-up Psychology of Addictive Behaviors. 17: 73-82. PMID 12665084 DOI: 10.1037/0893-164X.17.1.73  0.4
2003 Umbricht A, Hoover DR, Tucker MJ, Leslie JM, Chaisson RE, Preston KL. Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection. Drug and Alcohol Dependence. 69: 263-72. PMID 12633912 DOI: 10.1016/S0376-8716(02)00325-3  0.4
2003 Herning RI, Better WE, Tate K, Umbricht A, Preston KL, Cadet JL. Methadone treatment induces attenuation of cerebrovascular deficits associated with the prolonged abuse of cocaine and heroin. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 28: 562-8. PMID 12629538 DOI: 10.1038/sj.npp.1300073  0.4
2002 Preston KL, Umbricht A, Epstein DH. Abstinence reinforcement maintenance contingency and one-year follow-up Drug and Alcohol Dependence. 67: 125-137. PMID 12095662 DOI: 10.1016/S0376-8716(02)00023-6  0.4
2002 King VL, Stoller KB, Hayes M, Umbricht A, Currens M, Kidorf MS, Carter JA, Schwartz R, Brooner RK. A multicenter randomized evaluation of methadone medical maintenance. Drug and Alcohol Dependence. 65: 137-48. PMID 11772475 DOI: 10.1016/S0376-8716(01)00155-7  0.4
2001 Preston KL, Umbricht A, Wong CJ, Epstein DH. Shaping cocaine abstinence by successive approximation Journal of Consulting and Clinical Psychology. 69: 643-654. PMID 11550730 DOI: 10.1037//0022-006X.69.4.643  0.4
2000 Huestis MA, Cone EJ, Wong CJ, Umbricht A, Preston KL. Monitoring opiate use in substance abuse treatment patients with sweat and urine drug testing Journal of Analytical Toxicology. 24: 509-521. PMID 11043653  0.4
2000 Preston KL, Umbricht A, Epstein DH. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance Archives of General Psychiatry. 57: 395-404. PMID 10768702 DOI: 10.1001/ARCHPSYC.57.4.395  0.4
1999 Umbricht A, Montoya ID, Hoover DR, Demuth KL, Chiang CT, Preston KL. Naltrexone shortened opioid detoxification with buprenorphine. Drug and Alcohol Dependence. 56: 181-90. PMID 10529020 DOI: 10.1016/S0376-8716(99)00033-2  0.4
1999 Preston KL, Huestis MA, Wong CJ, Umbricht A, Goldberger BA, Cone EJ. Monitoring cocaine use in substance-abuse-treatment patients by sweat and urine testing Journal of Analytical Toxicology. 23: 313-322. PMID 10488917 DOI: 10.1093/jat/23.5.313  0.4
1999 Preston KL, Silverman K, Umbricht A, DeJesus A, Montoya ID, Schuster CR. Improvement in naltrexone treatment compliance with contingency management. Drug and Alcohol Dependence. 54: 127-35. PMID 10217552 DOI: 10.1016/S0376-8716(98)00152-5  0.4
1995 Montoya ID, Umbricht A, Preston KL. Buprenorphine for human immunovirus-positive opiate-dependent patients Biological Psychiatry. 38: 135-136. PMID 7578651 DOI: 10.1016/0006-3223(95)00071-N  0.4
Show low-probability matches.